SCHEMBL13392124

SCHEMBL13392124

CON=C(c1ccc(Cl)cc1Cl)C1CCN(C(=O)C2CCN(Cc3cnc(N)nc3)CC2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.42
▸ TSHR P16473 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ ADRB2 P07550 1/20 0.41
▸ SLC6A12 P48065 1/20 0.41
▸ KDM4E B2RXH2 3/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ EPHX2 P34913 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ ACKR3 P25106 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14188192 1.00 MEN1 (0.42) MEN1TSHRKMT2AALOX15MAPK1
SCHEMBL14188262 0.91 KMT2A (0.42) MEN1TSHRKMT2AALOX15MAPK1
SCHEMBL13392153 0.91 KMT2A (0.42) MEN1TSHRKMT2AALOX15MAPK1
SCHEMBL14188216 0.90 KMT2A (0.47) MEN1TSHRKMT2ASMN1; SMN2KDM4E
SCHEMBL13392094 0.90 KMT2A (0.47) MEN1TSHRKMT2ASMN1; SMN2KDM4E
SCHEMBL13391829 0.89 CYP3A4 (0.49) CYP3A4
SCHEMBL13391020 0.88 ALDH1A1 (0.44) MEN1TSHRKMT2ASMN1; SMN2ADRB2
SCHEMBL14078589 0.87 ADRB2 (0.44) MEN1TSHRKMT2AALOX15MAPK1
SCHEMBL13392088 0.87 ADRB2 (0.44) MEN1TSHRKMT2AALOX15MAPK1
SCHEMBL13392105 0.85 CYP3A4 (0.46) MEN1KMT2AALOX15KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093692-A1 PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN SCHERING CORPORATION SECHERING-PLOUGH CORPORATION (US) 2010-04-15 — — US disclosed
US-7300941-B2 Non-imidazole compounds SCHERING CORPORATION (US) 2007-11-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093692-A1 PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN GPR119, ATF4, GID4 MEN1 4556/4885TSHR 2742/4885KMT2A 3430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback